You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

63 Results
Guidelines and Advice
Status: Current
ID: GL-C50-12
Feb 2014
Guidelines and Advice
Status: Current
ID: GL-C50-13
Feb 2014
Guidelines and Advice
Status: Current
ID: GL-C50-11
Jan 2014
Guidelines and Advice
Status: Current
ID: GL-C50-14
Mar 2014
Statistical Reports
Jan 2014
Statistical Reports
Apr 2014
Guidelines and Advice
Status: Current
Jun 2014
Guidelines and Advice
Jul 2014
Guidelines and Advice
Status: Current
ID: GL-C50-15
Jun 2014
Drug
Other Name(s): Trelstar® (Allergan Pharma)
Quick Link(s):
Drug Monograph, Patient Info Sheet
Oct 2014
Regimen
Cancer Type:
Gastrointestinal, 
Gastrointestinal Stromal Tumours, 
Sarcoma, 
GIST
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant
Funding:
ODB - General Benefit
    iMAtinib - Refer to listed Health Canada indications for generic imatinib formulations. Patients must meet generic substitution policies for access to Gleevec®
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
iMAtinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Oct 2024
Regimen
Cancer Type:
Gastrointestinal, 
Gastrointestinal Stromal Tumours, 
Sarcoma, 
GIST
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    iMAtinib - Refer to listed Health Canada indications for generic imatinib formulations. Patients must meet generic substitution policies for access to Gleevec®
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
iMAtinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Oct 2024

Pages